Ambroxol was found to be safe and well tolerated in an open label trial in 18 people with Parkinson’s. It enters the brain and appears to increase levels of its chemical target GCase.
A phase II open label trial of a novel drug targeting
A prostrate drug (Terazosin) has been shown to exert neuroprotective effects in animal models.
AUDIO VERSION AVAILABLE.
anle138b shown to prevent clumping of alpha synuclein
Felodipine drug seen to improve neuronal survival
More continuous GLP1 targeting for neuroprotection